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Abstract
Telomerase is a reverse transcriptase associated with cellular immortality through telomere maintenance. This enzyme is
activated in 90% of human cancers, and inhibitors of telomerase are currently in clinical trials to counteract tumor growth.
Many aspects of telomerase biology have been investigated for therapy, particularly inhibition of the enzyme, but little was
done regarding its subcellular shuttling. We have recently shown that mutations in the nuclear export signal of hTERT, the
catalytic component of telomerase, led to a mutant (NES-hTERT) that failed to immortalize cells despite nuclear localization
and catalytic activity. Expression of NES-hTERT in primary fibroblast resulted in telomere-based premature senescence and
mitochondrial dysfunction. Here we show that expression of NES-hTERT in LNCaP, SQ20B and HeLa cells rapidly and
significantly decreases their proliferation rate and ability to form colonies in soft agar while not interfering with endogenous
telomerase activity. The cancer cells showed increased DNA damage at telomeric and extra-telomeric sites, and became
sensitive to ionizing radiation and hydrogen peroxide exposures. Our data show that expression of NES-hTERT efficiently
counteracts cancer cell growth in vitro in at least two different ways, and suggest manipulation with the NES of hTERT or its
subcellular shuttling as a new strategy for cancer treatment.
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Introduction
A key property of malignant tumors is their ability to proliferate
indefinitely. This is mediated, in 90% of the cases, by the
reactivation of telomerase, a reverse transcriptase responsible for
maintaining telomeres [1,2]. Telomerase is composed minimally of
two different subunits, a catalytic core (hTERT) and an RNA
component (hTR), which work in concert to replenish telomeres
with each cell division. hTERT has been recently shown to
acquire properties of an RNA-dependent RNA polymerase when
in a complex with the RNA component of the mitochondrial
endoribonuclease MRP [3]; such activity is not involved in the
maintenance of telomeres. Whereas hTR is present in both
somatic and germ cells constitutively, expression of hTERT is
tightly regulated. Telomerase activity is high during embryogen-
esis and in the vast majority of tumors, but is low or non-existent in
most adult somatic cells [1]. For that reason, inhibiting telomerase
has become a promising strategy for cancer treatment.
Several different approaches have been developed to block the
activity of telomerase holoenzyme, ranging from inhibitors of
hTERT to G-quadruplex stabilizing agents to targeted degrada-
tion of the associated hTR [4–17]. In all cases, direct or indirect
telomerase inhibition results in the inability of the cells to maintain
telomeres and ultimately cells arrest growth or die. A problem of
these approaches is that several weeks to months are required for
the effects as they mostly rely on extensive telomere shortening [5].
Nonetheless, telomerase inhibitors are currently in clinical trials
[18].
We have recently shown that a mutant hTERT defective in its
nuclear export signal (NES-hTERT) failed to maintain telomeres
and ‘‘healthy’’ mitochondria in both primary and SV40-
transformed human fibroblasts [19]. Despite nuclear localization
and catalytic activity in vitro, the mutant protein was biologically
inactive in vivo leading to premature senescence with activation of
the classical telomere-related DNA damage response (DDR), when
expressed in primary cells. Expression of the mutant protein was
also associated with mitochondrial dysfunction and DNA damage
to both telomeric and extra-telomeric sites [19]. Given the rapid
and dramatic effects observed, we hypothesized that ectopic
expression of NES-hTERT may also be an effective means to
counteract cancer cell growth. In the present study we expressed
NES-hTERT in various cancer cells lines and show a rapid and
efficient delay in cell cycle progression without any detectable
change in the levels of endogenous telomerase enzymatic activity.
Expression of the mutant protein significantly decreases the ability
of the cells for anchorage-independent growth in vitro. We found
that ectopic expression of NES-hTERT led to nuclear telomeric,
extra-telomeric and mitochondrial DNA (mtDNA) damage in the
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10812cancer cells and sensitized at least one type of cancer cells to both
oxidative stress and c-radiation. Taken together, our results
suggest targeting the NES of hTERT or its intracellular movement
as a novel strategy to effectively counteract tumor cell growth.
Results
Overexpression of NES-hTERT in skin and prostate cancer
cell lines rapidly blocks cell cycle progression
We have recently shown that ectopic expression of a mutant
hTERT in which the NES has been disrupted (NES-hTERT) causes
premature senescence in telomerase-negative human fibroblasts
[19]. Primary cells expressing NES-hTERT stopped growing within
5-20 population doublings after introduction of the mutant protein,
which was associated with classical signs of cellular senescence such
as blockade in the G1 to S transition, upregulation of p21
waf1,p 1 6
and positivity for senescence-associated b-galactosidase (b-gal)
activity [19]. Given these effects, we asked whether expression of
NES-hTERT would also impact cell cycle progression of telomerase-
positive cancer cells. To address this question, we stably expressed
NES-hTERT in SQ20B (squamous cell carcinoma - skin cancer) and
LNCaP (prostate cancer) cells and followed growth in mass cultures
for several weeks; control cells were either left non-infected or
infected with empty vector. No differences were observed between
non-infected and empty-vector transduced cells (data not shown).
Cells were selected with antibiotics for 2 weeks prior to initiation of
the experiments. Viral transductions were repeated at least two
independent times with each cell line showing reproducible results.
All experiments presented herein rely on data obtained with cells
derived from at least two independent viral infections.
It soon caught our attention that upon viral transduction
changes in the phenotype of the cells occurred; such changes were
observed while cells were still being selected. A fraction (,30–
50%) of SQ20B cells expressing NES-hTERT had flattened and
enlarged morphology with some of these cells showing multiple
nuclei (Fig. 1A, upper panels), reminiscent of the effects observed
in the primary cells [19]. Unlike in the primary fibroblasts, no
positive b-gal staining was observed in SQ20B cells expressing
NES-hTERT (data not shown), suggesting that the enlarged cells
were not senescent. These cells were also not apoptotic as they
were neither blebbing nor detaching from the dishes (data not
shown). Enlarged morphology was not observed in LNCaP cells
expressing the mutant hTERT; however, while these cells tend to
grow in clusters/foci irrespective of their confluence (see also
ATCC), expression of NES-hTERT suppressed this phenotype
(Fig. 1A, middle panels).
It is possible that these morphological changes simply result
from the non-specific integration of the NES-hTERT pBabe vector.
To rule out this possibility, we transiently transfected the mutant
protein in HeLa cells (adenocarcinoma). HeLa cells were chosen
because of the high efficiency of transient transfections (,60%) as
compared to both SQ20B and LNCaP cells (,10–20%; data not
shown) and because they too express endogenous telomerase. To
assure that the cells analyzed were expressing the mutant protein,
NES-hTERT was subcloned into the pCMV vector and either
transfected alone or co-transfected with GFP; results were
comparable with both approaches. Cells transfected with empty
pCMV vector (+ or 2 GFP) were used as negative controls. As can
be seen in Fig. 1A (right bottom panels), within 48 hours of
expression of the mutant protein, a fraction of HeLa cells also
showed enlarged and flattened morphology, which was not
observed in cells transfected with the vector control (Fig. 1A,
bottom left panel). These data suggest that the morphological
changes observed were associated specifically with expression of
NES-hTERT. Interestingly, no change in cell number was detected
for the first 96 h following transfections with construct of the
mutant protein (data not shown), while HeLa cells transduced with
vector control were doubling 48 h after transfection (Fig. 1A, left
bottom panel).
Next, we defined whether NES-hTERT altered cell cycle
progression of SQ20B and LNCaP cells using three different
approaches. First, we seeded similar number of cells stably
expressing or not the mutant protein and followed their growth
for a period of 6 days. At each time point (24, 72 and 144 hours)
cells were trypsinized and counted using a hemocytometer. As
shown in Fig. 1B, expression of NES-hTERT altered the
proliferation rate of both cell types. Under these conditions,
SQ20B cells underwent 1 population doubling every 28 hours
while SQ20B expressing the mutant hTERT doubled every
,36 hours. Times for doubling in the case of LNCaP cells and its
NES-hTERT derivative were estimated at 36 and 57 hours,
respectively (34 hours is the doubling time of LNCaP cells
according to the vendor (ATCC)). We then monitored cell cycle
progression by flow cytometry. Cells were synchronized by serum
withdrawal for 16–18 hours. At 8 hours after serum addition, cells
were collected and incubated with RNase A and propidium iodide
(PI). The data in Fig. 1C are representative of four independent
analyses; in both cell lines expression of NES-hTERT increased the
percentage of cells in G1 while it decreased the fraction of cells in
S (Fig. 1C). These data led us to quantify specifically the fraction of
cells in S phase based on tritiated thymidine incorporation.
Confluent cell populations were subcultured to lower density and
were incubated in the presence of [
3H]-thymidine. Movement into
S-phase was monitored by autoradiography at multiple time points
up to 72 hours after subculture. These experiments were
reproduced two independent times and clearly showed a
significant decrease in the percentage of cells in S phase upon
expression of the mutant protein (Fig. 1D), consistent with the
results obtained by flow cytometry. On average, by ,20–70 hours
after subculture, SQ20B and LNCaP cells expressing NES-hTERT
had 40% and 60–80% less cells in S phase, respectively, when
compared to their respective controls.
One can argue that high levels of hTERT could be driving the
cell cycle effects, as previously argued [20]. However, we do not
favor this hypothesis as ectopic expression of wild type (WT) or
R3E/R6E hTERT, a mutant hTERT that is unable to enter
mitochondria [21], had no effect on the proliferation rate of the
cells (data not shown). Other groups have also ectopically
expressed WT hTERT stably in various different types of cancer
cells and no defects in cell cycle progression were reported [22,23].
Taken together, the data in Fig. 1 show that expression of
NES-hTERT efficiently and rapidly delays progression of SQ20B
and LNCaP cells through the cell cycle.
Overexpression of NES-hTERT in skin and prostate cancer
cells decreases colony formation potential in vitro
A number of transformations are required for cells to become
tumorigenic, including increased growth rate and ability to grow
in an anchorage-independent manner [22–24]. The ability of
transformed cells to form colonies in soft agar is a useful in vitro
predictor of tumor formation in vivo [24]. We sought to investigate
whether the observed effects on proliferation rate after introduc-
tion of NES-hTERT in skin and prostate cancer cells would impact
their ability to form colonies in soft agar. To this end, we plated
equal number of SQ20B, LNCaP and their respective
NES-hTERT derivatives in triplicates in soft agar and allowed
them to grow for up to 3 weeks; colonies were counted every week
using crystal violet stain. Given the high amount of colonies
NES-hTERT Impacts Cell Cycle
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growth after 1 week of growth in which individual colonies were
still easily distinguishable. Results were reproduced two indepen-
dent times. Upper panels on Fig. 2 show the number of colonies
formed, lower panels show representative images of the plates. In
both cancer cell types, introduction of NES-hTERT significantly
decreased the number of colonies formed, suggesting decreased
tumorigenic potential of those cells compared to the respective
empty vector-expressing controls.
Expression of NES-hTERT does not alter the endogenous
levels of telomerase enzymatic activity but increases the
levels of telomeric and extra-telomeric DNA damage
Ectopic expression of a catalytically inactive mutant hTERT
that behaved as a dominant negative was shown to efficiently
inhibit telomerase enzymatic activity, leading to telomere erosion
and decreased proliferation of various cancer cell types. Increased
spontaneous apoptosis, decreased colony growth in soft agar and
diminished tumor formation in nude mice were also observed
[9,17]. Although NES-hTERT is enzymatically active in vitro, it is
unable to elongate telomeres in vivo [19]. Thus, it is possible that
in the telomerase-positive SQ20B and LNCaP cells, NES-hTERT
behaves in a dominant negative manner, ultimately leading to the
decreased proliferation rate noted above (Fig. 1). To test this
possibility, we analyzed levels of hTERT mRNA and telomerase
activity in whole cellular extracts of cells expressing or not NES-
hTERT using, respectively, RT-PCR and the telomeric repeat
amplification protocol (TRAP). As expected, RNA levels of
hTERT were increased in the cells ectopically expressing the
mutant (Fig. 3A). However, no changes in telomerase enzymatic
activity were observed by expression of the mutant protein as
judged by TRAP (Fig. 3B), indicating that NES-hTERT does not
exert a dominant negative effect upon the endogenous protein at
least in terms of enzymatic activity.
In telomerase negative fibroblasts, expression of NES-hTERT
leads to telomeric and extra-telomeric DNA damage [19]. Thus,
another possible explanation for the decrease in proliferation rate
is that NES-hTERT induces DNA damage in the cancer cells,
which in turn slows down their ability to progress through the cell
cycle. We tested this hypothesis by evaluating the presence of the
phosphorylated form of the histone H2A variant, cH2AX, and 53-
binding protein 1 (53BP1). We also detected DNA damage directly
at telomeres by immuno-fluorescence in situ hybridization
(immuno-FISH) in single cells, mtDNA damage was assessed by
gene-specific quantitative PCR (QPCR) [25–27].
Af o r mo fh i s t o n eH 2 Ap h o s p h o r y l a t e da ts e r i n e1 3 9( S 1 3 9o f
cH2AX) is essential for efficient recognition of DNA double strand
break (DSB) sites. Hundreds or thousands of cH2AX molecules
generate nuclear foci that can be found at the site of each incipient
DSB by immunostaining with antibodies to cH2AX [28–30]. 53BP1
is activated as part of the DNA damage response (DDR) and also
form foci [28,29,31]. We performed single cell analysis in SQ20B,
LNCaP cells and their respective NES-hTERT derivatives as we
previously described [19,29]. Cells were scored as having DNA
damage if they were positive for both cH2AX and 53BP1 foci.
Number and size of foci detected in each single cell were quantified
and are represented in Fig. 4A. In both cell lines the amount of foci
was significantly increased by expression of NES-hTERT (p=0.006
for SQ20B and 0.034 for LNCaP cells). It is noteworthy that
Figure 1. Cancer cells expressing NES-hTERT show changes in morphology and delays in cell cycle progression. (A) SQ20B (upper panels)
LNCaP (middle panels) and their derivatives stably expressing NES-hTERT were plated on dishes in equal numbers and analyzed 72 hours later. Phase
contrast images were taken on an Olympus IX70 microscope. Note enlarged morphology of SQ20B NES-hTERT and cells harboring multiple nuclei
(arrows). Clustering is observed in LNCaP (see box), but not seen in LNCaP NES-hTERT. Bottom panels show HeLa cells that were transiently transfected
with the NES-hTERT mutant. Images were taken 48 hours after transfections. Arrows indicate enlarged and multinucleated cells (middle) observed only
upon transfection with the mutant hTERT. (B) SQ20B, LNCaP and their NES-hTERT derivatives were plated and allowed to grow for up to 144 hours. At
various times cells were harvested and counted using a hemocytometer. In the case of LNCaP, cells were replated and counted again 72 hours later.
Mean of three analyses is shown, error bars represent s.e.m. (*p#0.05) (C) Percentage of cells in each phase of the cell cycle was calculated by flow
cytometry based on PI staining. (D) Cells were serum starved overnight, then released by serum addition. Cells were labeled with [
3H]-thymidine and
analyzed at scheduled time intervals for thymidine incorporation. Mean of two independent experiments is shown, error bars are s.d.
doi:10.1371/journal.pone.0010812.g001
Figure 2. Anchorage-independent growth is diminished by expression of NES-hTERT. 5610
3 cells/well of SQ20B, LNCaP and their
NES-hTERT derivatives were grown in soft agar for up to 3 weeks. Colony growth was evaluated every week and colonies counted based on crystal
violet staining. Graphs show results from colonies counted at 1 week when individual colonies, especially in the control cells, were still easily
distinguishable. Colonies were scored by two independent observers. Data shown are the average of two independent experiments done in
triplicates. Bars represent mean 6 sd. Representative images of the plates are shown below each graph.
doi:10.1371/journal.pone.0010812.g002
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presenting larger foci. For instance, the number of SQ20B
NES-hTERT cells showing 6 foci or more was 3-fold higher than
in SQ20B control cells (p=0.004) (Fig. 4A).
Next, we evaluated levels of telomere-induced foci (TIF), which
have been described as DNA damage foci presented at telomeric
sites. TIF can arise by gradual telomere erosion due to continuous
cell proliferation or by stochastic telomeric DNA damage [31–34].
We adopted a protocol that we previously described [29], and the
number of TIF positive cells was calculated based on the total
number of cells analyzed. A cell was considered TIF-positive when
50% of greater of DNA damage co-localized with telomeres. As
shown in Fig. 4B, the levels of TIF-positive cells were significantly
increased by expression of the mutant hTERT. Indeed, TIF-
positive cells increased about 2-fold in the LNCaP background
while in SQ20B this enhancement was less pronounced (Fig. 4B).
In SQ20B cells, the basal level of TIF was high: about 45% of the
cells were TIF-positive. Such high basal level of telomere damage
was unexpected since these cells express endogenous telomerase
that presumably maintains their telomeres. However, introduction
of NES-hTERT led to a further increase in TIF that was detected in
about 70% of all cells analyzed (Fig. 4B, bars on the left).
Finally, we analyzed mtDNA integrity by QPCR, as we
previously showed that expression of NES-hTERT was associated
with mitochondrial dysfunction, including loss of mtDNA integrity
in primary fibroblasts. Such effects were intimately linked to the
detected nuclear DNA damage at telomeric and extra-telomeric
sites [19].
Assuming that damage is randomly distributed, QPCR allows
an overall picture of the integrity of the genome under study
[25–27]. The assay measures integrity of DNA using long PCR
targets, in this case 8.9 kb in length, which is about 2/3 of the
entire mtDNA. Given identical conditions, DNA from control and
treated samples amplify differently depending on the number of
lesions present on the template by the time of the reaction. For
example, DNA from cells exposed to UV amplifies less than DNA
from the respective non-treated control [35]. The amount of
damage can be expressed as number of lesions per 10 kb assuming
a Poisson distribution of lesions on the template. Presence of
lesions reflects that the sample of interest amplifies less than its
control, while negative number of lesions can be observed when
the DNA of a given sample amplifies better than its respective
control. To monitor possible changes in mtDNA copy number, a
short fragment of the mitochondrial genome is also amplified in
order to normalize the data. Sensitivity limit of the technique is 1
lesion/10
5 bases (for more details on the assay, see references
[25–27] and [35].
The data in Fig. 4C reflect the average 6 s.e.m. of 3
independent analyses. Basal levels of lesions in the controls were
calculated based on the average amplification of the control
samples of each cell line, which was then used as a reference to
compare each individual control (for more details see the Methods
section). As expected, in both cellular backgrounds expression of
NES-hTERT significantly increased basal levels of mtDNA damage
(Fig. 4C), suggesting that mitochondrial dysfunction is also
amplified in the cancer cells by expression of the mutant protein.
Taken together, the data presented in Fig. 4 show that
expression of NES-hTERT in the telomerase-positive SQ20B and
LNCaP cells leads to DNA damage at telomeric and extra-
telomeric sites, which are not caused by a decrease in the levels of
active enzyme in the nucleus but may be associated with
dysfunctional mitochondria.
NES-hTERT increases sensitivity to genotoxic stress in skin
cancer cells
Expression of telomerase has been associated with modulation
of cell death induced by genotoxic agents. Sensitization,
promotion and no effects on apoptosis and/or necrosis have been
reported, which seem to rely on the type of cells under study, the
genotoxic agent used and, particularly, on the length of the
telomeres [17,36–45]. Given the significant increase in basal levels
of nuclear and mtDNA damage observed upon expression of the
mutant hTERT, we investigated whether the cells would be
further sensitized to genotoxic stress. For these experiments, we
selected SQ20B cells, which are known to be highly radioresistant
both in terms of DNA damage and loss of proliferative capacity
[46,47].
Figure 3. Expression of NES-hTERT does not alter endogenous levels of telomerase enzymatic activity. (A) Levels of hTERT RNA were
gauged by RT-PCR. GAPDH was amplified and used as loading control. (B) 100 ng of total cell extracts were used to perform the TRAP. Arrow
indicates internal control of the assay. Positive and negative controls are not shown.
doi:10.1371/journal.pone.0010812.g003
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137Cs c-rays.
SQ20B cells and its NES-hTERT derivative were plated at equal
numbers and were enriched in G1 for 48 hours prior to irradiation
by maintenance in the confluent state. This is important because
cells in different phases of the cell cycle differ in their radiation
sensitivity [48]. Cells were exposed to 1 Gray (Gy) of c- radiation
(0.65 Gy/min), and we analyzed nuclear DNA (nDNA) damage
by QPCR immediately after the exposure by monitoring integrity
of a 13.5 kb fragment of the b-globin gene [25–27]. Results
presented in Fig. 5A clearly demonstrate a significant increase in
the amount of c-ray-induced DNA damage in SQ20B NES-h-
TERT cells. Whereas in control SQ20B cells, 1 lesion is observed
in every 50 kb of the genome, the level of damage detected in
SQ20B NES-hTERT cells is 5-fold greater, translating to 1 lesion
every 10 kb of double stranded DNA (Fig. 5A).
Next we determined whether the cells would be sensitized to
other types of stresses. To this end, we exposed them to hydrogen
peroxide (H2O2) and analyzed cell death by flow cytometry. We
chose H2O2 because of our experience with this oxidative stressor;
experiments were performed as described by us previously
[21,49,50]. Briefly, equal number of SQ20B cells was seeded
16 hours prior to H2O2 exposures. Cells were treated with
200 mMH 2O2 for 60 minutes in basal medium in the absence of
FBS and were harvested either immediately following exposure to
H2O2 or allowed to recover for 24 hours in conditioned growth
medium. At both points, the amount of dead and apoptotic cells
was scored based on propidium iodide uptake (PI) and YOPRO-1
staining. YOPRO-1 is a green-fluorescent dye that detects
specifically apoptotic cells [51–55]. Cells were analyzed by flow
cytometry to quantify with greater confidence the percentage of
viable, dead and apoptotic cells. As no significant changes in these
parameters were observed immediately after the H2O2 treatment,
the data presented below relate to the 24 hours recovery point.
Figure 5B illustrates experiments that are representative of 3
independent analyses. A large increase in the amount of YOPRO-
1 and PI-positive cells was observed in the treated SQ20B
background expressing the mutant hTERT (Fig. 5B). Quantifica-
tion of the number of viable, dead and apoptotic cells revealed that
while a 2-fold increase in the number of dead cells (either PI-
positive only or PI and YOPRO positive) was observed in SQ20B
24 hours after the treatments, this increase was about 5-fold in
SQ20B expressing NES-hTERT (Fig. 5B). No significant differenc-
es in the basal rate of dead/apoptotic cells were detected when
comparing non-treated SQ20B with the mutant-expressing
derivative (Fig. 5B, upper panels).
To look for long-term effects of the treatments, we then followed
the proliferation rates of the control and treated SQ20B and
SQ20B NES-hTERT for 2 weeks after the H2O2 exposure. Equal
numbers of viable control and treated cells (0.5610
6) was plated
and their number counted using a hemocytometer in the first
24 hours and every time cells reached 100% confluence thereafter.
While controls and treated SQ20B doubled in number at least
once in the first 24 hours, no change in cell number was observed
in treated SQ20B NES-hTERT (Fig. 5C). Remarkably, these cells
remained quiescent for 2 additional weeks when they finally
started doubling (data not shown). These results are particularly
intriguing considering that SQ20B harbor a mutated p53 that is
unable to induce the G1-S checkpoint upon DNA damage
[46,47].
Taken together, the data shown in Fig. 5 demonstrate that
expression of NES-hTERT is able to sensitize SQ20B to c-radiation
and to oxidative stress caused by H2O2.
Discussion
In the present study we showed that introduction of
NES-hTERT, a mutant that is defective in nuclear-cytoplasmic
shuttling, into squamous carcinoma (SQ20B) and prostate cancer
(LNCaP) cells results in significant delays in cell cycle progression,
decreased proliferation rate and anchorage-independent growth
(Figs 1, 2). These effects were not associated with decreased
endogenous telomerase enzymatic activity since expression of the
mutant hTERT did not alter TRAP activity (Fig. 3). We also
observed increased DNA damage in telomeric and extra-telomeric
sites, and higher number of mtDNA lesions under normal
conditions upon expression of NES-hTERT (Fig. 4). Remarkably,
the hTERT mutant sensitized SQ20B cells that are otherwise
highly resistant to ionizing radiation-induced DNA damage and to
cell death induced by H2O2 (Fig. 5). Taken together, our data
suggest manipulating the NES of hTERT or telomerase’s
subcellular shuttling as novel and efficiently means to counteract
tumor cell growth.
NES-hTERT affects cell cycle and tumorigenicity of cancer
cells in vitro without behaving as a dominant negative
mutant
We have recently shown that expression of NES-hTERT in
primary cells leads to premature growth arrest with accompanying
morphological and genetic changes involved in cellular senescence
[19]. In the present study, we found similar changes in SQ20B and
LNCaP cells after expression of the mutant wherein a significant
decrease in the rates of cell cycle progression and proliferation
were observed, which was accompanied by alterations in cell
morphology (Fig. 1). However, no markers of senescence were
evident in the cells (data not shown). Further, significant decrease
in colony formation in soft agar was observed after introduction of
the mutant (Fig. 2), which likely resulted from decreased
proliferation rate and increased doubling time.
The lack of a complete growth arrest and the absence of
senescence markers in the cancer cell lines upon expression of
NES-hTERT were not surprising because activation and mainte-
nance of cellular senescence rely on the function of the tumor
suppressor p53, its downstream effector p21
waf1 and in the
activation of p16/pRb [56]. These signaling pathways are
defective, respectively, in SQ20B and LNCaP. While SQ20B
harbors a mutated p53 unable to transactivate p21
waf1, the p16
gene in LNCaP is subject to aberrant methylation, leading to
transcriptional inactivation and functional loss [47,57]. Given
these observations, it is tempting to speculate that activation of
both pathways is required for a complete growth arrest provoked
by expression of NES-hTERT. This hypothesis is supported by our
previous observations that expression of NES-hTERT in a SV40-
Figure 4. Expression of NES-hTERT increases nuclear and mitochondrial DNA damage in skin cancer and prostate cancer cells. (A)
Cells were immunostained with antibodies against cH2AX and against 53BP1. DNA was counterstained with DAPI. Graph shows percentage of cells
positive for both cH2AX and 53BP1 foci and the number and size of foci per cell (represented by the different colors according to the graph labeling).
Bars are mean 6 s.d. (B) ImmunoFISH staining to visualize simultaneously DNA damage foci and telomeres. DAPI was used to counterstain DNA.
Graph shows percentage of DNA damage foci localized at telomeres (TIF) per single cell. (C) mtDNA integrity was analyzed by QPCR in three
independent experiments. Graph show estimated lesion frequency 6 s.e.m.
doi:10.1371/journal.pone.0010812.g004
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no effects on cell cycle regulation [19].
It is yet unclear how NES-hTERT could impair the cell cycle of
SQ20B and LNCaP cells. One obvious possibility is that the
mutant competes with the endogenous protein, ultimately leading
to decreases in telomerase enzymatic activity that affects telomere
maintenance. This concept of dominant negative effect regarding
hTERT mutants is not new and has been shown to effectively halt
proliferation rate, as well as both in vitro and in vivo
tumorigenicity of various cancer cell types [9,17]. However, these
observations do not explain our data, since expression of
NES-hTERT did not alter the total levels of endogenous telomerase
activity as judged by the TRAP (Fig. 3). In addition, the effects of
the dominant-negative mutants previously reported were linked to
telomere shortening (due to the lack of telomere elongation) and
increases in basal apoptotic rate. Not surprisingly, the shorter the
telomeres were prior to expression of the dominant-negative
mutants the faster growth defects and cell death appeared [9,17].
We have not measured specifically telomeric length in the cells,
but results with immuno-FISH suggest that on average telomeres
of LNCaP cells were longer than in SQ20B cells, which had fairly
short telomeres prior to expression of the mutant. Even with initial
differences in their telomeric lengths, the proliferation defects
observed upon introduction of NES-hTERT were detected in the
same time frame (that is under the selection process) making it
unlikely that they relied on telomere shortening. In addition, no
increases in basal cell death rates were observed (Fig. 5 and data
not shown).
It is possible that NES-hTERT behaved as a dominant negative
in terms of subcellular shuttling, impeding the nuclear export of
the endogenous protein and ultimately leading to the same effects
as expression of NES-hTERT in telomerase-negative cells [19].
This possibility may also explain why cells expressing the mutant
hTERT have decreased mtDNA integrity (Fig. 4). We previously
found that NES-hTERT is not present in mitochondria, which was
associated with a high degree of mitochondrial dysfunction [19].
Our unpublished results show that a fraction of endogenous
hTERT is mitochondrial in both SQ20B and LNCaP cells
(Gordon and Santos, in preparation). Complete lack of mitochon-
drial hTERT in SQ20B and LNCaP cells could potentially drive
the degree of mitochondrial impairment, which is already
noteworthy in cancer cells [58], to a limit that impacts cell cycle
regulation either through increased reactive oxygen species (ROS)
and DNA damage, changes in oxygen utilization and/or energy
production. We did not monitor markers of mitochondrial
function per se but since the integrity of the mtDNA is intimately
associated with proper mitochondrial function [45,59] it is likely
that mitochondria are further impaired in the cancer cells
expressing NES-hTERT. More studies are required to better
understand this issue.
The high levels of DNA damage present in the cells upon
expression of the mutant protein (Fig. 4) may also play a role for
the cell cycle delays observed. One can envision that in the
presence of such high degree of damaged DNA, the cells need to
slow down in their progression through the cell cycle in order to
repair the damage [33]. Although the total levels of DNA foci were
already high in control cells, expression of the mutant increased
the level to a degree that was likely above the threshold that the
cells could ‘efficiently’ tolerate. In this regard, it is worth noting the
significant increase in the number of larger foci/cell after
expression of NES-hTERT (Fig. 4).
The flow cytometry analyses using PI revealed that the cells
were accumulating in the G1-S transition (Fig. 1). p53 is a master
regulator of DNA damage signaling involved particularly in the
G1-S checkpoint [60]. While the involvement of p53 could explain
the results in LNCaP cells, it does not apply for SQ20B cells that
harbor a defective version of the protein. It is likely that the latter
(or both cell lines) activate a yet different set of genes to trigger the
G1-S delay. One likely candidate is p38 MAPK, which can
contribute to the G1-S checkpoint in response to diverse stimuli in
a p53-independent manner. Interestingly, the contribution of p38
MAPK to the G1-S transition is particularly evident upon damage
by ROS and telomere-related senescence [61]. Further studies are
required to define which signaling pathway(s) involved in cell cycle
regulation is modulated in cancer cells by expression of
NES-hTERT.
The number of TIF positive cells significantly increased upon
expression of NES-hTERT. Although the number of TIF doubled
in LNCaP NES-hTERT compared to its control, a more modest
increase was observed for SQ20B cells. The latter may reflect the
fact that SQ20B NES-hTERT cells had many very short telomeres
that did not hybridize well (or at all) with the telomeric probe used
for the assay (data not shown). Irrespective, one intriguing
observation from this study was the high basal degree of TIF in
SQ20B cells even prior to expression of the mutant protein
(Fig. 4B). This is unexpected given these cells express endogenous
telomerase that is presumably functional at telomeres and thus
competent to sustain their replicative potential. These data may
indicate that the levels of telomerase that allow cell proliferation, at
least in this cancer cell line, are not the same required for
maintenance of a ‘functional’ telomeric structure. In accordance
with this assumption, Cesare and co-workers [62] recently
reported that immortalized human cell lines lacking wild-type
p53 spontaneously show many telomeres with a DNA damage
response (DDR). In telomerase-positive cells, DDR was associated
with low telomerase activity and short telomeres that were
proposed to represent an intermediate configuration between the
fully capped and uncapped (fusogenic) states [62].
Manipulation of hTERT subcellular localization may
provide a new therapeutic approach in cancer treatment
We show here that overexpression of NES-hTERT renders
SQ20B cells more sensitive to DNA damage caused by ionizing
radiation and to cell death-mediated by oxidative stress. More
unexpected, strong but transient growth arrest (for about 2 weeks)
was observed in the viable cells that were re-cultured after H2O2
exposures (Fig. 5). These results were very surprising owing to the
well-established radioresistance of SQ20B cells [47]. However,
they may reflect that only a small fraction of the mutant-expressing
Figure 5. NES-hTERT sensitizes skin cancer cells to genotoxic stress. (A) Nuclear DNA damage was estimated in SQ20B and its NES-hTERT
derivative immediately after exposure to 1 Gy of gamma radiation using QPCR. Results represent the average of three independent experiments 6
s.e.m. (B) Cells were treated with 200 mMo fH 2O2 for 60 minutes and allowed to recover for 24 hours in conditioned medium. At this point, cells were
harvested and the number of apoptotic, dead and viable cells was evaluated by flow cytometry using PI and YOPRO-1. Results are representative of
three independent experiments. (C) The same amount of viable cells (500,000) were replated after the H2O2 exposures and their growth rate was
followed for 2 weeks. The number of cells was counted using a hemocytometer at 24 hours and every time cells became confluent thereafter. As the
number of treated SQ20B NES-hTERT did not change in the following 2 weeks, only data for 24 hours post-treatment are shown. Results are mean of
three independent experiments 6 s.e.m. (* p#0.05).
doi:10.1371/journal.pone.0010812.g005
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to ionizing radiation given the conformation of the DNA [63].
Alternatively, it has been shown that GSH levels are lower in G1
and higher in S [64–66], which could explain the resistance of
SQ20B to cell death mediated by H2O2 while increasing sensitivity
of the mutant expressing cells. Finally, the additional stress
provoked by the exogenous damaging agents upon already heavily
damaged DNA may have pushed the cells towards death.
Associated with this is the presence of very short telomeres in
the mutant-expressing cells, which are known to be associated with
genomic instability [43]. More work is certainly required to
understand exactly how the NES-hTERT mutant can sensitize cells
to genotoxic damage and which kind of cell-tissue type would
positively respond to such intervention.
Materials and Methods
Cell Culture
SQ20B cells were grown in Eagle’s minimal essential medium
(Cellgro) supplemented with 10% fetal bovine serum (Gibco/
Invitrogen), 1% penicillin and streptomycin (Invitrogen) as
previously described [50]. LNCaP and HeLa cells were obtained
from ATCC. Cells were grown in Dulbecco’s modified Eagle high
glucose medium (Gibco/Invitrogen) supplemented with 10% fetal
bovine serum and 1% penicillin and streptomycin.
Plasmids and viral infections
Retroviral pBabe vector empty or carrying wild type or hTERT
mutants, and the pCMV vectors used were described earlier
[19,21,50]. Transient and stable transfections were performed as
described previously [21,50]. Images shown in Figure 1 were
acquired with an inverted Olympus IX70 microscope (80X) with
MicroFire digital camera.
Cell growth
Equal number of SQ20B and LNCaP cells and their respective
NES-hTERT derivatives were plated in 75 cm
2 flasks and followed
for up to 144 hours. At 24, 72 and 144 hours cells were harvested
by trypsinization and total number of attached cells was counted
with a hematocytometer.
Cell cycle analysis
Flow cytometry: SQ20B, LNCaP and their NES-hTERT mutant cells
were serum starved overnight (16–18 hours), then released from
serum starvation for 8 hours by addition of 10% FBS into the
medium. Cell cycle analysis by flow cytometry with propidium iodide
(PI, Molecular Probes) was performed as described earlier [19] using
a BD Biosciences FACSCalibur flow cytometer. DNA content
analysis was performed by Modi Fit LT (Verity Software House).
[
3H]thymidine labeling. SQ20B, LNCaP and their NES-hTERT
derivatives cells were serum starved for 48 hours, then trypsinized
and plated on 35 mm dishes (3610
4 cells per dish) in 2 ml of the
medium containing 2 mCi/mL of [
3H]-thymidine (specific activity
20 Ci/mmol) (PerkinElmer LAS, Inc), and 10% FBS. At regular
intervals, duplicate dishes were rinsed with PBS, fixed with
ethanol, and subjected to autoradiography. To determine labeling
indices, a minimum of 1000 cells/dish were scored. The use of this
continuous labeling technique allows precise determination of G1
delays [67]. The percentage of cells in S-phase was determined as
described [68].
Anchorage-independent growth in soft agar
SQ20B, LNCaP and their respective NES-hTERT derivative
cells were seeded on six-well plates at a density of 5610
3 cells in
2 ml of 0.3% agar layered onto 0.6% agar. Cells were grown for
up to 3 weeks, at 37uC in a humidified 5%CO2/95% air chamber,
and colonies were stained with crystal violet and counted every
week. Medium was replaced every 4–5 days or as needed.
Colonies were scored in a blinded fashion by two independent
observers.
DNA integrity by gene-specific quantitative PCR
QPCR was followed as described previously [25–27]. The
analyzed cells were derived in two independent viral infections. To
define the basal level of damage in the control cells, the relative
amplification of all control samples was averaged and used as a
reference to compare each individual control. Damage on the
mutant-expressing counterpart was estimated relative to the
non-NES-hTERT control. For more details on the assay see
references [25–27].
DNA damage foci
Cells were grown on coverslips for at least 48 hours prior to
immunostaining; they were then processed and stained with anti-
cH2AX and 53BP1 antibodies as described previously [19].
Images were acquired using a Zeiss Axiovert 200 fluorescence
microscope equipped with ApoTome.
TIF analysis by ImmunoFISH
Cells were processed and stained with anti-cH2AX and anti-
53BP1 antibodies as described above and protocol for TIF
followed as described [19,29]. Cells were mounted as described
above and analyzed by UV microscopy using a Zeiss Axiovert 200
fluorescence microscope equipped with ApoTome. Images were
acquired as z-stacks spaced 0.4 mm apart using a 100X lens with
1.4 optical aperture.
Telomeric Repeat Amplification Protocol (TRAP)
Total protein extracts (100 ng per sample) were assayed for
TRAP using TRAPeze kit (Chemicon) according to manufactur-
er’s instructions and with some modifications [50].
H2O2 treatment, cell viability and apoptosis
Cells were plated in 60-mm dishes (0.5610
6 cells per dish)
16 hours prior to the experiment. H2O2 experiments were
performed as described earlier [21,50]. Cells were either collected
immediately after the treatment or allowed to recover for 24 hours
in conditioned medium. Cell viability and apoptosis were analyzed
respectively with PI and YO-PRO-1 (Invitrogen) by flow
cytometry. Cells were treated for 1 h with 200 mMH 2O2 and
were allowed to recover for 24 hours when both control and
treated cells were harvested. Cells were washed twice with 1 ml of
PBS, and then stained with a final concentration of 2.5 mM of YO-
PRO-1 and 1 mg of PI for 20 minutes on ice. After this period, cells
were analyzed using a BD Biosciences FACSCalibur flow
cytometer. Percentage of apoptotic, dead and living cells were
scored using the Cellquest pro (BD Biosciences) software. Results
represent mean of at least three independent experiments.
Irradiation
Cells were enriched in G1 for 48 hours prior to irradiation by
maintenance in the confluent in serum-free medium for 48 hours.
The cells were irradiated with 1 Gy of c-rays (0.65 Gy/min) from
a
137Cs source in a ventilated irradiator (J.L. Shepherd, Mark I,
San Fernando, CA). Immediately prior to irradiation, the flasks
with the cells were placed on a rotating platform to ensure uniform
exposure dose per dish. After irradiation cells were collected for
NES-hTERT Impacts Cell Cycle
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independent experiments.
Statistical analysis
Unpaired Student t-test was performed to calculate statistical
significance (P#0.05).
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